Akebia Therapeutics
(AKBA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 335,001 | 207,742 | 181,227 | 1,535 | 0 |
| Cost of Goods | 145,336 | 7,768 | N/A | N/A | N/A |
| Gross Profit | 189,665 | 199,974 | 181,227 | 1,535 | N/A |
| Operating Expenses | 476,289 | 378,903 | 257,901 | 137,995 | 61,513 |
| Operating Income | -286,288 | -178,161 | -76,674 | -136,460 | -61,513 |
| Interest Expense | -792 | 0 | 0 | 0 | 0 |
| Other Income | -794 | 6,235 | 3,003 | 713 | 797 |
| Pre-tax Income | -286,290 | -171,926 | -73,671 | -135,747 | -60,716 |
| Income Tax | -6,631 | -28,338 | N/A | N/A | N/A |
| Net Income Continuous | -279,659 | -143,588 | -73,671 | -135,747 | -60,716 |
| Net Income | $-279,659 | $-143,588 | $-73,671 | $-135,747 | $-60,716 |
| EPS Basic Total Ops | -2.36 | -2.47 | -1.69 | -3.60 | -2.29 |
| EPS Basic Continuous Ops | -2.36 | -2.47 | -1.69 | -3.60 | -2.29 |
| EPS Diluted Total Ops | -2.36 | -2.47 | -1.69 | -3.60 | -2.29 |
| EPS Diluted Continuous Ops | -2.36 | -2.47 | -1.69 | -3.60 | -2.29 |
| EPS Diluted Before Non-Recurring Items | -1.63 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-248,461 | $-176,972 | $-75,447 | $-135,670 | $-60,859 |